Arsanis is a biotechnology company dedicated to the development
of human antibody based therapeutics against severe infectious diseases. According to an SEC filing, the company has raised a $4 million debt financing. Arsanis has recently initiated a Phase 1 study of its lead product candidate, ASN100, an antibody combination designed to prevent and treat serious Staph infections. Existing investors include OrbiMed, NeoMed, Polaris Partners and SV Life Sciences.